Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

AVEO Pharmaceuticals Inc

+ Add to Watchlist

AVEO:US

1.8200 USD 0.1000 5.21%

As of 20:10:00 ET on 04/27/2015.

Snapshot for AVEO Pharmaceuticals Inc (AVEO)

Open: 1.9200 Day's Range: 1.7473 - 1.9700 Volume: 1,392,433
Previous Close: 1.9200 52wk Range: 0.6050 - 2.1700 1-Yr Rtn: +40.00%

Stock Chart for AVEO

No chart data available.
  • AVEO:US 1.8200
  • 1D
  • 1M
  • 1Y
1.9200
Interactive AVEO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AVEO

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7818
Est. EPS (USD) (12/2015) -0.6770
Est. PEG Ratio -
Market Cap (M USD) 100.11
Shares Outstanding (M) 55.01
30 Day Average Volume 1,172,235
Price/Book (mrq) 4.6184
Price/Sale (ttm) 5.1864
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AVEO

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AVEO

Aveo Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. The Company's lead product candidate is an oral inhibitor of the vascular endothelial growth factor, or VEGF,receptors.

Michael P BaileyPresident/CEOKeith S EhrlichChief Financial Officer
Michael N NeedleChief Medical Ofcr:Aveo OncologyJoseph VittiglioSenior VP/General Counsel
More Company Profile & Key Executives for AVEO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil